Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18101558 | 0.96 | TNKS (0.34) | TDP1L3MBTL1NQO1TNKSPARP1 | |
| SCHEMBL18101540 | 0.90 | TNKS (0.31) | TNKSPARP1TNKS2HDAC6PARP2 | |
| SCHEMBL18101526 | 0.89 | TNKS (0.32) | TNKSPARP1TNKS2HDAC6PARP2 | |
| SCHEMBL18101563 | 0.88 | TNKS (0.36) | NQO1TNKSPARP1TNKS2HDAC6 | |
| SCHEMBL18101508 | 0.88 | TDP1 (0.35) | TDP1L3MBTL1ERBB2CYP1A2FYN | |
| SCHEMBL18101547 | 0.88 | ALOX5 (0.34) | TNKSPARP1TNKS2HDAC6PARP2 | |
| SCHEMBL18101560 | 0.87 | TNKS (0.31) | TNKSPARP1TNKS2HDAC6PARP2 | |
| SCHEMBL18101555 | 0.87 | NPC1 (0.30) | — | |
| SCHEMBL18101546 | 0.87 | LMNA (0.30) | — | |
| SCHEMBL4078997 | 0.87 | SIGMAR1 (0.34) | TDP1L3MBTL1TNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3196198-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME | Idemitsu Kosan Co., Ltd (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-20160284998-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160284998-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160284998-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME | EPB41, RPS4X, OR10J3 | TDP1 3706/4885L3MBTL1 1745/4885NQO1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.